Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
Evaluate them separately from your core semaglutide program rather than bundling everything together and losing visibility into what you are actually paying for
4 Current therapeutic landscape and unmet need While resmetirom (a THR- agonist) has recently gained FDA approval for the treatment of MASH (in patients with fibrosis F2-F3), marking the first-ever pharmacological agent for this condition (Liu et al., 2025), there remains no single FDA-approved drug that effectively prevents or reverses the progression of advanced SLD to HCC
Subtypes of atopic dermatitis: from phenotype to endotype
It has antioxidant and antibacterial activity and can be used synergistically with IT-preservative phenoxyethanol or 1,2-Hexanediol and Caprylyl Glycol to form a broad spectrum preservative system for cosmetic formulas
I mean, do you think that-- are all of these different drugs, with all the different names, are they all equally safe